Lacosamide Accord

Lacosamide, the active ingredient in Lacosamide Accord, is a sodium channel blocker presented as an oral formulation for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication that modulates neuronal sodium channels.

- Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. - Epilepsy: provides adjunctive therapy to improve overall seizure control. - Refractory focal epilepsy: helps achieve better seizure management when other treatments are insufficient.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Nausea: upset stomach often accompanied by an urge to vomit. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or lacking energy. - Blurred vision: temporary loss of visual clarity. - Diplopia: double vision, especially at higher doses.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Cardiac arrhythmias: irregular heart rhythms, particularly in patients with pre‑existing conduction disorders. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe hepatic injury: marked elevation of liver enzymes or liver failure. - Life‑threatening skin reactions: toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS).

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction disorders: use caution in patients with known arrhythmias or AV‑node disease. - Pregnancy: risk category is unknown; discuss potential benefits and risks with the patient. - Concomitant antiepileptics: monitor for additive CNS effects and possible pharmacokinetic interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may lower lacosamide plasma concentrations, reducing effectiveness. - Strong CYP2C19 inhibitors (e.g., fluconazole): can increase lacosamide exposure, raising toxicity risk. - Other sodium‑channel blockers (e.g., phenytoin): may enhance cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Valproate: combined use may increase CNS side‑effects; monitor patient tolerance. - Alcohol: concurrent consumption can intensify dizziness and sedation. - Other antiepileptics: additive side‑effects may require dose adjustments.